Healthcare Value Capital, LLC
Follow13F filer, CIK 1458461, Woodcliff Lake, NJ
Healthcare Value Capital, LLC reported $39,165,000 across 19 holdings for the quarter ended 2020-06-30, in a 13F-HR filed 2020-08-14. Its ten largest share positions make up 79.72% of the portfolio.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000919574-20-005187
- Period
- 2020-06-30
- Reported value
- $39.2M
- Holdings
- 19
- Top 10 weight
- 79.72%
- New
- 0
- Sold out
- 7
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| MENLO THERAPEUTICS INCadded | +850,000 | $1.47M |
| INVESCO QQQ TRUST SERIES 1added | +100,000 | $1.18M |
| WALGREENS BOOTS ALLIANCE INCadded | +25,000 | $1.06M |
| GREENLANE HLDGS INCadded | +25,000 | $99.5K |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| AZNexited | -75,000 | -$3.35M |
| LABORATORY CRP OF AMER HLDGSexited | -25,000 | -$3.16M |
| ALEXION PHARMACEUTICALS INCexited | -30,000 | -$2.69M |
| ABBVreduced | -25,000 | -$2.46M |
| MCKreduced | -15,000 | -$2.3M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q2 2020
Share positions as resolved from 13F-HR 0000919574-20-005187, largest first. % of portfolio is the value over $34,719,000, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| GLAXOSMITHKLINE PLC-ADRGLAXOSMITHKLINE PLC-ADR | 100,000 | $4.08M | 11.75% | 0 | |||
| GILDGILEAD SCIENCES INC | 50,000 | $3.85M | 11.08% | 0 | Timeline | ||
| INVESCO QQQ TRUST SERIES 1INVESCO QQQ TRUST SERIES 1 | 250,000 | $2.95M | 8.5% | +100,000 | |||
| MENLO THERAPEUTICS INCMENLO THERAPEUTICS INC | 1,700,000 | $2.94M | 8.47% | +850,000 | |||
| TYME TECHNOLOGIES INC COMTYME TECHNOLOGIES INC COM | 2,175,000 | $2.89M | 8.33% | 0 | |||
| CAHCARDINAL HEALTH INC | 50,000 | $2.61M | 7.52% | -25,000 | Timeline | ||
| ABBVABBVIE INC | 25,000 | $2.46M | 7.07% | -25,000 | Timeline | ||
| WALGREENS BOOTS ALLIANCE INCWALGREENS BOOTS ALLIANCE INC | 50,000 | $2.12M | 6.11% | +25,000 | |||
| JAZZJAZZ PHARMACEUTICALS PLC | 19,000 | $2.1M | 6.04% | -11,000 | Timeline | ||
| CLOVIS ONCOLOGY INCCLOVIS ONCOLOGY INC | 250,000 | $1.69M | 4.86% | 0 | |||
| CVSCVS HEALTH CORP | 25,000 | $1.62M | 4.68% | 0 | Timeline | ||
| MCKMCKESSON CORP | 10,000 | $1.53M | 4.42% | -15,000 | Timeline | ||
| CORCENCORA INC | 15,000 | $1.51M | 4.35% | -15,000 | Timeline | ||
| ANTARES PHARMA INCANTARES PHARMA INC | 500,000 | $1.38M | 3.96% | 0 | |||
| GREENLANE HLDGS INCGREENLANE HLDGS INC | 250,000 | $995K | 2.87% | +25,000 |
Options
Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).
| Security | Type | Amount | Value | Change |
|---|---|---|---|---|
| INVESCO QQQ TRUST SERIES 1INVESCO QQQ TRUST SERIES 1 ULTRAPRO SHORT S | call | 200,000 | $2.36M | +125,000 |
| VKTXVIKING THERAPEUTICS INC COM | call | 100,000 | $721K | 0 |
| AMARIN CORP PLCAMARIN CORP PLC SPONS ADR NEW | call | 100,000 | $692K | -100,000 |
| CLOVIS ONCOLOGY INCCLOVIS ONCOLOGY INC COM | call | 100,000 | $675K | 0 |
Sold out in Q2 2020
Positions in the previous quarter's report that this quarter's report no longer lists.
| Security | Shares before | Value before | Type |
|---|---|---|---|
| GILDGILEAD SCIENCES INC | 50,000 | $3.74M | call |
| AZNASTRAZENECA PLC-SPONS ADR | 75,000 | $3.35M | shares |
| LABORATORY CRP OF AMER HLDGSLABORATORY CRP OF AMER HLDGS | 25,000 | $3.16M | shares |
| SPXLDIREXION SHARES ETF TRUST | 120,000 | $3.13M | call |
| ALEXION PHARMACEUTICALS INCALEXION PHARMACEUTICALS INC | 30,000 | $2.69M | shares |
| PROSHARES TR ULTSH NASD BIOTPROSHARES TR ULTSH NASD BIOT | 75,000 | $1.06M | call |
| ADAMAS PHARMACEUTICALS INCADAMAS PHARMACEUTICALS INC | 200,000 | $578K | call |
How Q2 2020 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000919574-20-005187 | base | 2020-08-14 | acceptance time not in the bulk data set |